Dysregulation of NEUROG2 plays a key role in focal cortical dysplasia.

OBJECTIVE: Focal cortical dysplasias (FCDs) are an important cause of drug-resistant epilepsy. In this work, we aimed to investigate whether abnormal gene regulation, mediated by microRNA, could be involved in FCD type II. METHODS: We used total RNA from the brain tissue of 16 patients with FCD type II and 28 controls. MicroRNA expression was initially assessed by microarray. Quantitative polymerase chain reaction, in situ hybridization, luciferase reporter assays, and deep sequencing for genes in the mTOR pathway were performed to validate and further explore our initial study. RESULTS: hsa-let-7f (p = 0.039), hsa-miR-31 (p = 0.0078), and hsa-miR34a (p = 0.021) were downregulated in FCD type II, whereas a transcription factor involved in neuronal and glial fate specification, NEUROG2 (p < 0.05), was upregulated. We also found that the RND2 gene, a NEUROG2-target, is upregulated (p < 0.001). In vitro experiments showed that hsa-miR-34a downregulates NEUROG2 by binding to its 5'-untranslated region. Moreover, we observed strong nuclear expression of NEUROG2 in balloon cells and dysmorphic neurons and found that 28.5% of our patients presented brain somatic mutations in genes of the mTOR pathway. INTERPRETATION: Our findings suggest a new molecular mechanism, in which NEUROG2 has a pivotal and central role in the pathogenesis of FCD type II. In this way, we found that the downregulation of hsa-miR-34a leads to upregulation of NEUROG2, and consequently to overexpression of the RND2 gene. These findings indicate that a faulty coupling in neuronal differentiation and migration mechanisms may explain the presence of aberrant cells and complete dyslamination in FCD type II. Ann Neurol 2018;83:623-635.

Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study.

Progressive functional decline in the epilepsies is largely unexplained. We formed the ENIGMA-Epilepsy consortium to understand factors that influence brain measures in epilepsy, pooling data from 24 research centres in 14 countries across Europe, North and South America, Asia, and Australia. Structural brain measures were extracted from MRI brain scans across 2149 individuals with epilepsy, divided into four epilepsy subgroups including idiopathic generalized epilepsies (n =367), mesial temporal lobe epilepsies with hippocampal sclerosis (MTLE; left, n = 415; right, n = 339), and all other epilepsies in aggregate (n = 1026), and compared to 1727 matched healthy controls. We ranked brain structures in order of greatest differences between patients and controls, by meta-analysing effect sizes across 16 subcortical and 68 cortical brain regions. We also tested effects of duration of disease, age at onset, and age-by-diagnosis interactions on structural measures. We observed widespread patterns of altered subcortical volume and reduced cortical grey matter thickness. Compared to controls, all epilepsy groups showed lower volume in the right thalamus (Cohen's d = -0.24 to -0.73; P < 1.49 × 10-4), and lower thickness in the precentral gyri bilaterally (d = -0.34 to -0.52; P < 4.31 × 10-6). Both MTLE subgroups showed profound volume reduction in the ipsilateral hippocampus (d = -1.73 to -1.91, P < 1.4 × 10-19), and lower thickness in extrahippocampal cortical regions, including the precentral and paracentral gyri, compared to controls (d = -0.36 to -0.52; P < 1.49 × 10-4). Thickness differences of the ipsilateral temporopolar, parahippocampal, entorhinal, and fusiform gyri, contralateral pars triangularis, and bilateral precuneus, superior frontal and caudal middle frontal gyri were observed in left, but not right, MTLE (d = -0.29 to -0.54; P < 1.49 × 10-4). Contrastingly, thickness differences of the ipsilateral pars opercularis, and contralateral transverse temporal gyrus, were observed in right, but not left, MTLE (d = -0.27 to -0.51; P < 1.49 × 10-4). Lower subcortical volume and cortical thickness associated with a longer duration of epilepsy in the all-epilepsies, all-other-epilepsies, and right MTLE groups (beta, b < -0.0018; P < 1.49 × 10-4). In the largest neuroimaging study of epilepsy to date, we provide information on the common epilepsies that could not be realistically acquired in any other way. Our study provides a robust ranking of brain measures that can be further targeted for study in genetic and neuropathological studies. This worldwide initiative identifies patterns of shared grey matter reduction across epilepsy syndromes, and distinctive abnormalities between epilepsy syndromes, which inform our understanding of epilepsy as a network disorder, and indicate that certain epilepsy syndromes involve more widespread structural compromise than previously assumed.

Is inpatient ictal video-electroencephalographic monitoring mandatory in mesial temporal lobe epilepsy with unilateral hippocampal sclerosis? A prospective study.

OBJECTIVE: To compare surgical outcome in mesial temporal lobe epilepsy (MTLE) patients with unilateral hippocampal sclerosis (MTLE-HS) who had or did not have preoperative video-electroencephalographic monitoring (VEEG). METHODS: A prospective study was undertaken with 166 consecutive pharmacoresistant unilateral MTLE-HS patients. All patients were investigated with detailed seizure semiology, serial routine outpatient EEG, magnetic resonance imaging, neuropsychological evaluation, and if necessary, other examinations. Postoperative follow-up ranged between 2 and 16 years. Patients were divided into: (1) patients operated on based on routine outpatient EEG information, with >80% of EEGs with unilateral interictal epileptiform discharges (IEDs) ipsilateral to HS or ictal events (n = 71); and (2) patients submitted to preoperative VEEG (n = 95). To avoid the bias generated by ictal recordings, we performed a subanalysis of: (1) patients without preoperatively ictal recordings (n = 80) and (2) patients with ictal recordings in VEEG or routine outpatient EEG (n = 86). RESULTS: Groups were similar regarding gender, age at surgery, seizure onset, preoperative seizure frequency, and duration of follow-up. Overall, 136/166 (81.92%) were classified as Engel I seizure outcome, with no difference between groups; 76.84% and 88.73% of patients with and without VEEG, respectively, had Engel I postoperative seizure outcome (P = .77). The time lag until surgery was shorter in the group without VEEG (80 vs 38 months; P = .01). Considering ictal recordings, 76.74% of patients with seizures recorded and 87.50% without ictal recordings had Engel I outcome (P = .11). SIGNIFICANCE: We performed the first prospective study in a tertiary epilepsy center comparing surgical outcomes in unilateral MTLE-HS patients investigated preoperatively with and without VEEG. Based on the surgical outcome, VEEG is not imperative in patients with unilateral MTLE-HS who have compatible semiology and clearly ipsilateralized IEDs evaluated by a multidisciplinary and experienced epilepsy group.

Progression of gray matter atrophy in seizure-free patients with temporal lobe epilepsy.

OBJECTIVES: To investigate the presence and progression of gray matter (GM) reduction in seizure-free patients with temporal lobe epilepsy (TLE). METHODS: We enrolled 39 consecutive TLE patients, seizure-free for at least 2 years--20 with magnetic resonance imaging (MRI) signs of hippocampal sclerosis (TLE-HS), 19 with normal MRI (TLE-NL), and 74 healthy controls. For longitudinal analysis, we included individuals who had a second MRI with minimum interval of 18 months: 21 patients (10 TLE-HS, 11 TLE-NL) and 11 controls. Three-dimensional (3D) T1 -weighted images acquired in 3 Tesla MRI were analyzed with voxel-based morphometry (VBM). The images of patients with right-sided interictal epileptogenic zone (EZ) were right-left flipped, as well as a comparable proportion of controls. Cross-sectional analysis: The patients' images from each group were compared to controls to investigate differences in GM volumes. Longitudinal analysis: The first and second images were compared in each group to look for decreased GM volume. RESULTS: Cross-sectional analysis: Patients with TLE-HS had diffuse GM atrophy, including hippocampus and parahippocampal gyrus, insula, frontal, and occipital lobes ipsilateral to EZ, bilateral thalamus and contralateral orbitofrontal gyrus, and caudate. In contrast, TLE-NL group did not present significant differences compared to controls. Longitudinal analysis: TLE-HS presented progressive GM reduction in ipsilateral insula and occipital lobe, contralateral motor area, and bilateral temporal and frontal lobes. TLE-NL had GM progression in ipsilateral hypothalamus and parietal lobe, contralateral cerebellum, and bilateral temporal lobe. Controls did not show changes in GM volume between MRIs. SIGNIFICANCE: Diffuse extrahippocampal GM atrophy is present in seizure-free patients with TLE-HS. In addition, there is progressive GM atrophy in patients with and without HS. These results demonstrate that not only ongoing seizures are involved in the progression of GM atrophy. An underlying pathologic mechanism could be responsible for progressive brain volume loss in TLE patients even in seizure-free periods.

Memory impairment is not necessarily related to seizure frequency in mesial temporal lobe epilepsy with hippocampal sclerosis.

OBJECTIVE: To investigate the effect of seizure frequency on memory, we performed a cross sectional study comparing mesial temporal lobe epilepsy (MTLE) patients with frequent and infrequent seizures. METHODS: We performed magnetic resonance imaging (MRI) hippocampal volume (HV) measurements and neuropsychological assessment in 22 patients with frequent seizures (at least one dyscognitive seizure [DS] per month) that were refractory to antiepileptic drugs and 20 patients with infrequent seizures (three or less DS per year and no event evolving to a bilateral convulsive seizure), all with MRI signs of hippocampal sclerosis (HS) on visual analysis. We also included 29 controls for comparison of volumetric data. RESULTS: There was no difference in memory performance between patients with frequent seizures and infrequent seizures. We observed a significant bilateral reduction of HV in patients with MTLE when compared to controls (p < 0.001). The degree of hippocampal atrophy (HA) between patients with frequent and infrequent seizures was not different. There was a negative correlation between seizure frequency and HV, with r = -0.3 for the HV ipsilateral to the HS and r = -0.55 for the contralateral side, thus, explaining only 9% and 30% of the HV loss. There was a positive correlation between age of onset and degree of HA (r = 0.37). SIGNIFICANCE: Our data suggest that seizure frequency does not explain most of the HV loss or memory impairment in MTLE. Memory impairment appears to be more influenced by hippocampal damage than by seizure frequency. Further studies are necessary to identify the factors that influence memory decline in patients with MTLE.

Amygdala enlargement occurs in patients with mesial temporal lobe epilepsy and hippocampal sclerosis with early epilepsy onset.

Mesial temporal lobe epilepsy (MTLE) associated with hippocampal sclerosis (HS) is considered an electroclinical syndrome, and there is a debate whether it is a unique disease or an entity with distinct subtypes. Together with other mesial temporal structures, the amygdala is important in the epileptogenic network of patients with MTLE with HS. During automatic volumetric analysis of mesial structures in a group of 102 patients with MTLE with MRI signs of HS, we observed significant amygdala enlargement in 14 (14%) individuals compared to a group of 79 healthy subjects. The increased amygdala volume was contralateral to the epileptogenic zone and MRI signs of HS in 93% of these patients. Patients with MTLE with HS and enlarged amygdala had significantly earlier epilepsy onset than those without an increase of amygdala volumes. Mesial temporal lobe epilepsy with HS and enlarged amygdala may be a part of the spectrum of this condition.

Automated Online Quantification Method for 18F-FDG Positron Emission Tomography/CT Improves Detection of the Epileptogenic Zone in Patients with Pharmacoresistant Epilepsy.

AIMS: To assess the validity of an online method to quantitatively evaluate cerebral hypometabolism in patients with pharmacoresistant focal epilepsy as a complement to the visual analysis of the 18F-FDG positron emission tomography (PET)/CT exam. METHODS: A total of 39 patients with pharmacoresistant epilepsy and probable focal cortical dysplasia [22 patients with frontal lobe epilepsy (FLE) and 17 with temporal lobe epilepsy (TLE)] underwent a presurgical evaluation including EEG, video-EEG, MRI, and 18F-FDG PET/CT. We conducted the automated quantification of their 18F-FDG PET/CT data and compared the results with those of the visual-PET analysis conducted by experienced nuclear medicine physicians. For each patient group, we calculated Cohen's Kappa coefficient for the visual and quantitative analyses, as well as each method's sensitivity, specificity, and positive and negative predictive values. RESULTS: For the TLE group, both the visual and quantitative analyses showed high agreement. Thus, although the quantitative analysis could be used as a complement, the visual analysis on its own was consistent and precise. For the FLE group, on the other hand, the visual analysis categorized almost half of the cases as normal, revealing very low agreement. For those patients, the quantitative analysis proved critical to identify the focal hypometabolism characteristic of the epileptogenic zone. Our results suggest that the quantitative analysis of 18F-FDG PET/CT data is critical for patients with extratemporal epilepsies, and especially those with subtle MRI findings. Furthermore, it can easily be used during the routine clinical evaluation of 18F-FDG PET/CT exams. SIGNIFICANCE: Our results show that quantification of 18F-FDG PET is an informative complementary method that can be added to the routine visual evaluation of patients with subtle lesions, particularly those in the frontal lobes.

MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy.

Epilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting consequences. Recently, circulating microRNAs have emerged as potential biomarkers in a number of clinical scenarios. The purpose of this study was to identify and to validate circulating microRNAs that could be used as biomarkers in the diagnosis of epilepsy. Quantitative real-time PCR was used to measure plasma levels of three candidate microRNAs in two phases of study: an initial discovery phase with 14 patients with mesial temporal lobe epilepsy (MTLE), 13 with focal cortical dysplasia (FCD) and 16 controls; and a validation cohort constituted of an independent cohort of 65 patients with MTLE and 83 controls. We found hsa-miR-134 downregulated in patients with MTLE (p = 0.018) but not in patients with FCD, when compared to controls. Furthermore, hsa-miR-134 expression could be used to discriminate MTLE patients with an area under the curve (AUC) of 0.75. To further assess the robustness of hsa-miR-134 as a biomarker for MTLE, we studied an independent cohort of 65 patients with MTLE, 27 of whom MTLE patients were responsive to pharmacotherapy, and 38 patients were pharmacoresistant and 83 controls. We confirmed that hsa-miR-134 was significantly downregulated in the plasma of patients with MTLE when compared with controls (p < 0.001). In addition, hsa-miR-134 identified patients with MTLE regardless of their response to pharmacotherapy or the presence of MRI signs of hippocampal sclerosis. We revealed that decreased expression of hsa-miR-134 could be a potential non-invasive biomarker to support the diagnosis of patients with MTLE.

Patterns of seizure control in patients with mesial temporal lobe epilepsy with and without hippocampus sclerosis.

OBJECTIVE: Patients with mesial temporal lobe epilepsy (MTLE) may present unstable pattern of seizures. We aimed to evaluate the occurrence of relapse-remitting seizures in MTLE with (MTLE-HS) and without (MTLE-NL) hippocampal sclerosis. METHOD: We evaluated 172 patients with MTLE-HS (122) or MTLE-NL (50). Relapse-remitting pattern was defined as periods longer than two years of seizure-freedom intercalated with seizure recurrence. "Infrequent seizures" was considered as up to three seizures per year and "frequent seizures" as any period of seizures higher than that. RESULTS: Thirty-seven (30%) MTLE-HS and 18 (36%) MTLE-NL patients had relapse-remitting pattern (X2, p = 0.470). This was more common in those with infrequent seizures (X2, p < 0.001). Twelve MTLE-HS and one MTLE-NL patients had prolonged seizure remission between the first and second decade of life (X2, p = 0.06). CONCLUSION: Similar proportion of MTLE-HS or MTLE-NL patients present relapse-remitting seizures and this occurs more often in those with infrequent seizures.

A Locus Identified on Chromosome18P11.31 is Associated with Hippocampal Abnormalities in a Family with Mesial Temporal Lobe Epilepsy.

We aimed to identify the region harboring a putative candidate gene associated with hippocampal abnormalities (HAb) in a family with mesial temporal lobe epilepsy (MTLE). Genome-wide scan was performed in one large kindred with MTLE using a total of 332 microsatellite markers at ∼12 cM intervals. An additional 13 markers were genotyped in the candidate region. Phenotypic classes were defined according to the presence of hippocampal atrophy and/or hyperintense hippocampal T2 signal detected on magnetic resonance imaging. We identified a significant positive LOD score on chromosome 18p11.31 with a Z(max) of 3.12 at D18S452. Multipoint LOD scores and haplotype analyses localized the candidate locus within a 6-cM interval flanked by D18S976 and D18S967. We present here evidence that HAb, which were previously related mainly to environmental risk factors, may be influenced by genetic predisposition. This finding may have major impact in the study of the mechanisms underlying abnormalities in mesial temporal lobe structures and their relationship with MTLE.

MRI and EEG as long-term seizure outcome predictors in familial mesial temporal lobe epilepsy.

OBJECTIVE: To evaluate the natural history and outcome predictors in familial mesial temporal lobe epilepsy (FMTLE). METHODS: We conducted a longitudinal study of 103 individuals from 17 FMTLE families (mean follow-up: 7.6 years). We divided subjects into 3 groups: FMTLE (n = 53), unclassified seizure (n = 18), and asymptomatics (n = 32). We divided FMTLE patients into 3 subgroups: seizure-free (n = 19), infrequent (n = 17) seizures, and frequent (n = 17) seizures and further reclassified them into favorable and poor outcome. We defined hippocampal atrophy (HA) by visual MRI analysis and performed volumetry in those who had 2 MRIs. RESULTS: FMTLE patients with infrequent seizures evolved to either frequent seizures (17.6%) or seizure freedom (23.5%). In the seizure-free group, most remained seizure-free and 21% developed infrequent seizures. All patients with frequent seizures remained in the same status or underwent surgery. Twelve percent of the asymptomatics and 22% of the unclassified-seizure group evolved to FMTLE with infrequent seizures. Predictive factors of poor outcome were presence of HA (p = 0.0192) and interictal epileptiform discharges (p = 0.0174). The relationship between initial precipitating incidents and clinical outcome was not significant although a tendency was observed (p = 0.055). Use of antiepileptic drugs and secondary generalized seizures during the patient's lifetime did not predict poor outcome. We observed progression of HA only in the group with frequent seizures. CONCLUSION: Most patients with FMTLE continued in the same clinical status. However, patients with frequent seizures had progression of HA and none improved except those who underwent surgery. Interictal epileptiform discharges and HA predicted poorer outcome in FMTLE, and there was a tendency in favor of initial precipitating incidents as outcome predictors.

Late onset temporal lobe epilepsy due to cerebral hypoperfusion: case report / Epilepsia de lobo temporal de início tardio decorrente de hipoperfusão cerebral: relato de caso / Epilepsia de lóbulo temporal de inicio tardío debido a hipoperfusión cerebral: relato de caso

Temporal lobe epilepsy is the most common form of focal epilepsy. The main pathological substrate of refractory TLE is hippocampal sclerosis (HS). HS has been associated with prolonged febrile and recurrent seizures. Other known causes for hippocampal injury are head trauma, ischemia, stroke and Alzheimer's disease. The exact causes of HS remain unknown, although they are probably diverse and multifactorial. The patient with TLE had no risk factors for epilepsy. His first seizure occurred immediately after an abdominal surgery complicated by profuse bleeding and hypotension during the procedure. The MRI showed hippocampal atrophy, probably due to hippocampal hypoperfusion, given the temporal relationship between the seizures and surgery. The etiology of hippocampal infarcts is discussed in this article. In a study with animal model, cerebral hypoperfusion led to a pattern of epileptiform activity similar to that found in the human hippocampus.

A epilepsia de lobo temporal (ELT) é a forma mais comum de epilepsia focal. O principal substrato patológico da ELT refratária é a esclerose hipocampal (EH). A EH tem sido associada a crises febris prolongadas e convulsões recorrentes. Outras causas conhecidas de dano hipocampal são: traumatismo cranioencefálico, isquemia, acidente vascular cerebral e doença de Alzheimer. As causas exatas da EH permanecem desconhecidas, apesar de serem provavelmente diversas e multifatoriais. O paciente com ELT não tinha fatores de risco de epilepsia. O paciente apresentou a primeira crise epiléptica no pós-operatório imediato de uma cirurgia abdominal complicada por sangramento profuso e hipotensão durante o procedimento. A RM evidenciou atrofia hipocampal, provavelmente decorrente da hipoperfusão hipocampal, dada a relação temporal das crises com o procedimento cirúrgico. A etiologia dos infartos hipocampais é abordada neste artigo. Em um estudo com modelo animal, o hipofluxo cerebral levou a um padrão de atividade epileptiforme semelhante ao encontrado no hipocampo humano.

La epilepsia de lóbulo temporal (ELT) es la forma más común de epilepsia focal. El principal sustrato patológico de la ELT refractaria es la esclerosis hipocampal (EH). La EH ha sido asociada a crisis febriles prolongadas y convulsiones recurrentes. Otras causas conocidas de daño hipocampal son: traumatismo craneoencefálico, isquemia, accidente vascular cerebral y enfermedad de Alzheimer. Las causas exactas de la EH permanecen desconocidas, a pesar de ser probablemente diversas y multifactoriales. El paciente con ELT no tenía factores de riesgo de epilepsia. El paciente presentó la primera crisis epiléptica en el postoperatorio inmediato de una cirugía abdominal complicada por sangrado profuso e hipotensión durante el procedimiento. La RM evidenció atrofia hipocampal, probablemente debido a la hipoperfusión hipocampal, dada la relación temporal de las crisis con el procedimiento quirúrgico. La etiología de los infartos hipocampales es abordada en este artículo. En un estudio con modelo animal, el hipoflujo cerebral llevó a un estándar de actividad epileptiforme semejante al encontrado en el hipocampo humano.

Patterns of seizure control in patients with mesial temporal lobe epilepsy with and without hippocampus sclerosis / Padrões de controle de crises em pacientes com epilepsia de lobo temporal com ou sem esclerose hipocampal

Objective Patients with mesial temporal lobe epilepsy (MTLE) may present unstable pattern of seizures. We aimed to evaluate the occurrence of relapse-remitting seizures in MTLE with (MTLE-HS) and without (MTLE-NL) hippocampal sclerosis. Method We evaluated 172 patients with MTLE-HS (122) or MTLE-NL (50). Relapse-remitting pattern was defined as periods longer than two years of seizure-freedom intercalated with seizure recurrence. “Infrequent seizures” was considered as up to three seizures per year and “frequent seizures” as any period of seizures higher than that. Results Thirty-seven (30%) MTLE-HS and 18 (36%) MTLE-NL patients had relapse-remitting pattern (X2, p = 0.470). This was more common in those with infrequent seizures (X2, p < 0.001). Twelve MTLE-HS and one MTLE-NL patients had prolonged seizure remission between the first and second decade of life (X2, p = 0.06). Conclusion Similar proportion of MTLE-HS or MTLE-NL patients present relapse-remitting seizures and this occurs more often in those with infrequent seizures. .

Objetivo Pacientes com epilepsia do lobo temporal mesial (ELTM) podem apresentar padrão instável de crises epilépticas. Nosso objetivo foi avaliar ocorrência de crises remitente-recorrentes em ELTM com (ELTM-EH) e sem (ELTM-NL) esclerose hipocampal. Método Avaliamos 172 pacientes com ELTM-EH (122) ou ELTM-NL (50). Padrão remitente-recorrente foi definido como períodos superiores a dois anos de remissão intercalados com recorrência de crises. Até três crises por ano foram consideradas como "infrequentes" e qualquer período com frequência maior como "frequentes". Resultados Trinta e sete (30%) pacientes com ELTM-EH e 18 (36%) com ELTM-NL apresentaram crises remitente-recorrentes (X2, p = 0,470), mais comum naqueles com crises infrequentes (X2, p < 0,001). Doze pacientes com ELTM-EH e um ELTM-NL apresentaram remissão prolongada de crises entre a primeira e a segunda década de vida (X2, p = 0,06). Conclusão Proporção semelhante de pacientes com ELTM-EH e ELTM-NL apresentam crises remitente-recorrentes e isso ocorre com maior frequência em pacientes com crises esporádicas. .

Late diagnosis of limbic encephalitis associated with LGI1 antibodies leading to relapses / Diagnóstico tardio de encefalite límbica associada a anticorpos LGI1 que levam a recidivas / Diagnóstico tardío de encefalitis límbica asociada a anticuerpos LGI1 que llevan a recidivas

Autoimmune encephalitis has been a subject of research in the past few years; most of the cases are non-paraneoplastic and associated with an antibody to a surface protein of neurons. Studies have shown that VGKC complex is indeed represented by three proteins, and LGI1 is the most prevalent in limbic encephalitis. This entity is characterized by monophasic presentation with acute or subacute onset, memory loss, confusion, seizures and psychiatric symptoms. The presentation of anti-LGI1 antibodies in serum or CSF confirms the diagnosis. The treatment consists of immunotherapy with good clinical response, which is a criterion for diagnosis. We report a case of a patient with diagnosis confirmed six months after the symptoms onset, improvement after immunotherapy, but with episodes of relapse.

A encefalite autoimune tem sido assunto de pesquisa nos últimos anos, a maioria dos casos é não paraneoplásica e associada ao anticorpo para uma proteína de superfície dos neurônios. Estudos têm mostrado que o complexo VGKC é efetivamente representado por três proteínas, e a LGI1 é a mais prevalente na encefalite límbica. Essa entidade é caracterizada por apresentação monofásica com início agudo ou subagudo, perda de memória, confusão mental, crises convulsivas e sintomas psiquiátricos. A apresentação de anticorpos anti-LGI1 no soro ou no LCE confirma o diagnóstico. O tratamento consiste em imunoterapia com boa resposta clínica, que é um critério diagnóstico. Relatamos o caso de um paciente com diagnóstico confirmado seis meses após o início dos sintomas, com melhora após imunoterapia, porém com episódios de recaídas.

La encefalitis autoinmune ha sido asunto de investigación en los últimos años; la mayoría de los casos es no paraneoplásica y asociada al anticuerpo para una proteína de superficie de las neuronas. Estudios han mostrado que el complejo VGKC es efectivamente representado por tres proteínas, y la LGI1 es la más prevalente en la encefalitis límbica. Esa entidad es caracterizada por presentación monofásica con inicio agudo o subagudo, pérdida de memoria, confusión mental, crisis convulsivas y síntomas psiquiátricos. La presentación de anticuerpos anti-LGI1 en el suero o en el LCE confirma el diagnóstico. El tratamiento consiste en inmunoterapia con buena respuesta clínica, que es un criterio diagnóstico. Relatamos el caso de un paciente con diagnóstico confirmado seis meses después del inicio de los síntomas, con mejora después de inmunoterapia, aunque con episodios de recaídas.

Fragile X Syndrome and Epilepsy: case report / Síndrome do X Frágil e Epilepsia: relato de caso

Introduction: Learning disabilities is defined by intelligence quotient of less than or equal to 70 associated with limited learning functions such as cognition, language, motor function and social skills activities. Epilepsy is more common in individuals with learning disabilities and its frequency increases progressively considering severe intellectual impairment. Fragile X syndrome is the most common genetic cause of learning disability and 10-20% of these children have epilepsy. Methods: We describe a patient with fragile X syndrome, who had febrile seizures leading to temporal lobe epilepsy. Results: Male patient, 36 years old. He had several episodes of febrile seizures from one to seven years old and at the age of 27 he started with spontaneous dyscognitive seizures with possible temporal lobe origin. His brother, who also has the diagnosis of fragile X syndrome, presented a single afebrile seizure as a child. Patient's MRI showed left hippocampal atrophy. Conclusion: The relationship between febrile seizure and temporal lobe epilepsy in the context of fragile X syndrome is discussed in this article. Fragile X syndrome turns patients morevulnerable to have any kind of seizures. Therefore, we have to prevent febrile seizures in these patients...

Introdução: O déficit de aprendizagem é definido por quociente de inteligência inferior ou igual a 70 associado às funções limitadas de aprendizagem, tais como a cognição, a linguagem, a função motora e as habilidades sociais. Epilepsia é mais comum em indivíduos com dificuldades de aprendizagem e sua incidência aumenta progressivamente em pacientes com deficiência intelectual grave. Síndrome do X Fragil é a causa genética mais comum de deficiência de aprendizado e 10-20% destas crianças têm epilepsia. Métodos: Nós descrevemos um paciente com síndrome do X frágil, que teve convulsões febris e evoluiu com epilepsia do lobo temporal. Resultados: O paciente apresentou dois episódios de convulsão febril durante a infância e, com 27 anos, iniciou crises discognitivas típicas de lobo temporal. Seu irmão, que também tem síndrome do X frágil, apresentou crise afebril única na infância. A RM do paciente mostrou atrofia hipocampal à esquerda. Conclusão: A relação entre a convulsão febril e epilepsia do lobo temporal no contexto da síndrome do X frágil é discutida neste artigo. Pacientes com síndrome do X frágil são mais suscetíveis a ter qualquer tipo de crise epiléptica. Portanto, temos que tentar evitar crise febril prolongada nestes pacientes...

Long term follow up of familial mesial temporal lobe epilepsy / Evolução da epilepsia de lobo temporal mesial familiar

OBJECTIVE: To analyze seizure outcome in individuals with familial mesial temporal lobe epilepsy (FMTLE). METHOD: We followed prospectively 64 individuals with FMTLE and 37 asymptomatic individuals belonging to 28 families. RESULTS: Patients with FMTLE had a mean follow up was 93.4 ± 15.8 months. At baseline they were divided in benign (n = 29), remission (n = 28) and refractory (n = 7). At last follow up visit 41.4 percent patients with benign FMTLE remained classified as benign, 20.7 percent became refractory and 37.9 percent were in remission. In the subgroup of FMTLE in remission 21 75 percent remained without seizures; 21.4 percent were classified as benign FMTLE, and one died (3.6 percent) from cause unrelated to epilepsy. All refractory patients remained refractory. From the asymptomatic group, 10.8 percent became symptomatic (FMTLE). The mean follow up was 76.0 ± 21.2 months. CONCLUSION: Prospective follow up of more than 7 years in patients with FMTLE revealed that it is unlikely to achieve seizure control in those with refractory seizures. Patients with diagnose of more benign forms of FMTLE for more than one year are likely to either remit or remain under well controlled seizures. The majority of patients who had achieved seizure remission remained seizure-free and none became refractory. Asymptomatic individuals had a greater probability to have seizures compared to the general population in a 6 year period of follow up.

OBJETIVOS: Analisar a evolução de famílias com epilepsia de lobo temporal mesial familiar (ELTMF). METODOLOGIA: Seguimento prospectivo de 64 pacientes com ELTMF e 37 membros assintomáticos pertencente a 28 famílias. RESULTADOS: A média de seguimento dos pacientes com ELTMF foi de 93,4 ± 15,8 meses. Na avaliação inicial os pacientes foram divididos em benignos (n = 29), remissão (n = 28) e refratários (n = 7). Na última visita disponível, 41,4 por cento dos pacientes com ELTMF benigna permaneceram classificados como benignos, 20,7 por cento tornaram-se refratários e 37,9 por cento entraram em remissão. No grupo em remissão, 75 por cento permaneceram livres de crise, 21,4 por cento foram classificados como benignos e um faleceu (3,6 por cento) de causa não relacionada à epilepsia. Todos pacientes refratários permaneceram refratários. Em relação aos assintomáticos 10,8 por cento evoluíram com crises. A média de seguimento dos assintomáticos foi de 76,0 ± 21,2 meses. CONCLUSÃO: O seguimento prospectivo de mais de 7 anos de pacientes com ELTMF revelou que é improvável ocorrer controle de crises no grupo refratário. No grupo benigno é muito provável que estes indivíduos entrem em remissão ou permaneçam com evolução benigna. A maioria dos pacientes do grupo em remissão permaneceu em remissão e nenhum se tornou refratário. Em relação aos assintomáticos a probabilidade de apresentar uma crise no decorrer de aproximadamente 6 anos foi maior que o observado na população geral.